Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

Desloratadine

&times

Overview

What is Desloratadine?

The desloratadine orally disintegrating tablets light red colored, speckled, round, flat, uncoated, beveled edged debossed with “R” on one side and “551” on the other side for the 2.5 mg tablets and a “light red colored, speckled, round, flat, uncoated, beveled edged debossed with “RDY” on one side and “360” on the other side  for the 5 mg tablets. Each orally disintegrating tablet contains either 5 mg or 2.5 mg of desloratadine. It also contains the following inactive ingredients: anhydrous citric acid, aspartame, colloidal silicon dioxide, crospovidone, ferric oxide, mannitol, lactose anhydrous, microcrystalline cellulose, polacrilex resin, sodium stearyl fumarate, talc, tutti frutti flavor. 

Desloratadine is a white to light pink colored powder that is soluble in dichloromethane. It has an molecular formula: CHClNand a molecular weight of 310.8. The chemical name is 8-chloro-6,11-dihydro-11-(4-piperdinylidene)-5H-benzo[5,6]cyclohepta[1,2-b]pyridine and has the following structure:



What does Desloratadine look like?



What are the available doses of Desloratadine?

Desloratadine orally disintegrating tablets 2.5 mg are light red colored, speckled, round, flat, uncoated, beveled edged debossed with “R” on one side and “551” on the other side. 

Desloratadine orally disintegrating tablets 5 mg are light red colored, speckled, round, flat, uncoated, beveled edged debossed with “RDY” on one side and “360” on the other side. 

What should I talk to my health care provider before I take Desloratadine?

How should I use Desloratadine?

 Desloratadine orally disintegrating tablets may be taken without regard to meals. Place desloratadine orally disintegrating tablets on the tongue and allow to disintegrate before swallowing. Tablet disintegration occurs rapidly. Administer with or without water. Take tablet immediately after opening the blister.


What interacts with Desloratadine?

Sorry No Records found


What are the warnings of Desloratadine?

Sorry No Records found


What are the precautions of Desloratadine?

Sorry No Records found


What are the side effects of Desloratadine?

Sorry No records found


What should I look out for while using Desloratadine?

Desloratadine orally disintegrating tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see and ]


What might happen if I take too much Desloratadine?

In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis.

Information regarding acute overdosage is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the desloratadine product. In a dose-ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported.

In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of desloratadine 45 mg for 10 days [See ].

Lethality occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended daily oral dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposures were approximately 290 times the human daily oral dose on a mg/m basis). No deaths occurred at oral doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were approximately 810 times the human daily oral dose on a mg/m basis).


How should I store and handle Desloratadine?

Unopened vials of gemcitabine for injection, USP are stable until the expiration date indicated on the package when stored at controlled room temperature 20° to 25°C (68° to 77°F) and that allows for excursions between 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature] [].Desloratadine Orally Disintegrating Tablets 2.5 mg: Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)Desloratadine Orally Disintegrating Tablets 5 mg: Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)Storage:Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Desloratadine Orally Disintegrating Tablets 2.5 mg: Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)Desloratadine Orally Disintegrating Tablets 5 mg: Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)Storage:Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Desloratadine Orally Disintegrating Tablets 2.5 mg: Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)Desloratadine Orally Disintegrating Tablets 5 mg: Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)Storage:Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Desloratadine Orally Disintegrating Tablets 2.5 mg: Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)Desloratadine Orally Disintegrating Tablets 5 mg: Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)Storage:Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Desloratadine Orally Disintegrating Tablets 2.5 mg: Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)Desloratadine Orally Disintegrating Tablets 5 mg: Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)Storage:Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Desloratadine Orally Disintegrating Tablets 2.5 mg: Carton of 5 packs (NDC 55111-551-31), each pack containing 6 tablets (55111-551-06)Desloratadine Orally Disintegrating Tablets 5 mg: Carton of 5 packs (NDC 55111-360-31), each pack containing 6 tablets (55111-360-06)Storage:Store orally disintegrating tablets at 20°-25°C (68°-77°F) excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature].


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Desloratadine is a long-acting tricyclic histamine antagonist with selective H-receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2 to 3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H-receptor. Desloratadine inhibited histamine release from human mast cells in vitro. Results of a radiolabeled tissue distribution study in rats and a radioligand H-receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown.

Non-Clinical Toxicology
Desloratadine orally disintegrating tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see and ]

The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including non-steroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta-adrenergic blocking agents. When such drugs are administered to a patient receiving glyburide, the patient should be observed closely for hypoglycemia. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for loss of control.

An increased risk of liver enzyme elevations was observed in patients receiving glyburide concomitantly with bosentan. Therefore concomitant administration of glyburide and bosentan is contraindicated.

Certain drugs tend to produce hyperglycemia and may lead to loss of control. These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid. When such drugs are administered to a patient receiving glyburide, the patient should be closely observed for loss of control. When such drugs are withdrawn from a patient receiving glyburide, the patient should be observed closely for hypoglycemia.

A possible interaction between glyburide and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide. The mechanism for this interaction is not known.

A potential interaction between oral miconazole and oral hypoglycemic agents leading to severe hypoglycemia has been reported. Whether this interaction also occurs with the intravenous, topical or vaginal preparations of miconazole is not known.

The following adverse reactions are discussed in greater detail in other sections of the label:

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).